Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis

Pediatric Nephrology

Volumn 21, Issue 7, 2006, Pages 962-966

  Tanaka, Hiroshi ^a   Tsugawa, Koji ^a   Suzuki, Koichi ^a   Nakahata, Tohru ^a   Ito, Etsuro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Anti dsDNA antibody; Disease flare; Lupus nephritis; Mizoribine; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOUBLE STRANDED DNA ANTIBODY; MIZORIBINE; PREDNISOLONE;

ADOLESCENT; ADULT; AMENORRHEA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CALCULATION; CHILD; CLINICAL ARTICLE; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; GIRL; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RELAPSE; REMISSION; SINGLE DRUG DOSE; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LUPUS NEPHRITIS; RIBONUCLEOSIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745108063     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0120-8     Document Type: Article

References (25)

1. Kamata K, Okubo M, Uchiyama T, Masaki Y, Kobayashi Y, Tanaka T (1984) Effect of mizoribine on lupus nephropathy of New Zealand black/white F1 hybrid mice. Clin Immunol Immunopathol 33:31-38
2. Sonda K, Takahashi K, Tanabe K, Fuchinoue S, Hayasaka Y, Kawaguchi H, Teraoka S, Toma H, Ota K (1996) Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 28:3643-3648
3. Yokota S (2002) Mizoribine: Mode of action and effects in clinical use. Pediatr Int 44:196-198
4. Hamasaki T, Mori M, Kinoshita Y, Saeki T, Sakano T (1997) Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatr Nephrol 11:625-627
5. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S (2000) A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58:317-324
6. Kawasaki Y, Suzuki J, Sakai N, Etoh S, Murai H, Nozawa R, Suzuki H (2004) Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy. Am J Nephrol 24:147-153
7. Hirayama K, Kobayashi M, Hashimoto Y, Usui J, Shimizu Y, Hirayama A, Yoh K, Yamagata K, Nagase S, Nagata M, Koyama A (2004) Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis 44:57-63
8. Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, Waga S (2004) Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol 62:412-417
9. Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, Naito M, Koike M, Nitta K, Nihei H (2005) Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol 64:28-34
10. Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji YL, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156-1162
11. Mok CC, Lai KN (2002) Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 40:447-557
12. Yumura W, Uchida K, Kawashima A, Kobayashi H, Miwa N, Honda K, Nitta K, Nihei H (1999) Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients (in Japanese). Jin to toseki (Kidney and Dial, Tokyo) 47:705-708
13. Tanaka H, Suzuki K, Nakahata T, Sato T, Ito E (2003) Mizoribine oral pulse therapy for a patient with severe lupus nephritis. Pediatr Int 45:488-490
14. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S (2003) Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol 60:390-394
15. Tanaka H, Nakahata T, Tsugawa K, Tsuruga K, Yumura W, Ito E (2004) Mizoribine pulse therapy for patients with flares of lupus nephritis: A one-year observation. Clin Nephrol 62:165-166
16. Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E (2005) Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol 63:417-422
17. Tanaka H, Tateyama T, Waga S (2001) Methylprednisolone pulse therapy in Japanese children with severe lupus nephritis. Pediatr Nephrol 16:817-819
18. Austin HA, Balow JE (1999) Natural history and treatment of lupus nephritis. Semin Nephrol 19:2-11
19. Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158-166
20. Yang LY, Chen WP, Lin CY (1994) Lupus nephritis in children. A review of 167 patients. Pediatrics 94:335-340
21. Abe Y, Tsuji Y, Hisano M, Nakada M, Miura K, Watanabe S, Odajima Y, Iikura Y (2004) Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis. Pediatr Int 46:597-600
22. Shibasaki T, Matsuyama H, Gomi H, Usui M, Ishimoto F, Sakai O (1996) Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside. Am J Nephrol 16:167-172
23. Tanaka H, Tsugawa K, Nakahata T, Kudo M, Onuma S, Kimura S, Ito E (2005) Mizoribine pulse therapy for a pediatric patient with steroid-resistant nephrotic syndrome. Tohoku J Exp Med 205:87-91
24. Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H (2005) Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:96-98
25. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H (2000) Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 274:87-92